Filing Flows › Xenetic Biosciences (XBIO) › Q2 2026 › vs Q1 2026
Xenetic Biosciences (XBIO) Q2 2026 vs Q1 2026 (quarter over quarter)
Xenetic Biosciences's revenue fell $146K (-18%) from $807K in Q1 2026 to $661K in Q2 2026.
Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%, net loss $930K, operating cash flow −$875K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $661K | $807K | −$146K | -18% |
| Other income, net | $42K | $46K | −$4K | -8% |
| Net loss | $930K | $456K | $473K | +104% |
| Costs & expenses | $1.6M | $1.3M | $323K | +25% |
| Operating costs | $1.6M | $1.3M | $323K | +25% |
| Research & development | $552K | $661K | −$109K | -17% |
| General & admin | $1.1M | $648K | $433K | +67% |
| Operating cash sources | $930K | $456K | $473K | +104% |
| Share-based compensation | $52K | $11K | $41K | +359% |
| Working capital & other | $2K | −$91K | $94K | — |
| Cash used in operations | $875K | $536K | $339K | +63% |
| Net loss absorbed | $930K | $456K | $473K | +104% |
Questions
How much did Xenetic Biosciences's revenue grow quarter over quarter in Q2 2026?
Xenetic Biosciences's revenue fell $146K (-18%) from $807K in Q1 2026 to $661K in Q2 2026.